ASPEN PHARMACARE HOLDINGS LIMITED - Completion of the Acquisition of a Portfolio of Products in Latin America from Viatris

Completion of the Acquisition of a Portfolio of Products in Latin America from Viatris

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) ("Aspen Holdings")
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively "Aspen" or the "Group")

COMPLETION OF THE ACQUISITION OF A PORTFOLIO OF PRODUCTS IN LATIN AMERICA FROM VIATRIS

Shareholders are referred to the announcement of 1 August 2023 wherein it was confirmed that Aspen
Global Incorporated, incorporated in Mauritius, a wholly owned subsidiary of Aspen Holdings, had executed
an agreement pursuant to which it would acquire from Viatris Inc. the commercialisation rights and related
intellectual property for a portfolio of well-known branded products in Latin America (the "Transaction").

Aspen is pleased to confirm that the Transaction closed on 1 November 2023.

The key products within the portfolio are sold under the brand names Lipitor, Viagra, Lyrica, Zoloft, Norvasc,
and Celebrex.


Durban
01 November 2023

Sponsor
Investec Bank Limited

Date: 01-11-2023 10:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.